Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.35 HKD | -2.88% | -4.93% | -7.53% |
Apr. 03 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
Apr. 03 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
Sales 2023 | 56.6M 7.83M 61.11M | Sales 2024 * | - | Capitalization | 1.3B 180M 1.41B |
---|---|---|---|---|---|
Net income 2023 | -145M -20.07M -157M | Net income 2024 * | -219M -30.31M -236M | EV / Sales 2023 | -15.6 x |
Net cash position 2023 | 2.27B 314M 2.45B | Net cash position 2024 * | 2B 277M 2.16B | EV / Sales 2024 * | - |
P/E ratio 2023 |
-9.85
x | P/E ratio 2024 * |
-6.35
x | Employees | 219 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 27.46% |
1 day | -2.88% | ||
1 week | -4.93% | ||
Current month | +3.85% | ||
1 month | +3.85% | ||
3 months | -27.03% | ||
6 months | -26.63% | ||
Current year | -7.53% |
Managers | Title | Age | Since |
---|---|---|---|
Jinzi Wu
CEO | Chief Executive Officer | 61 | - |
Yan Yuemei
CTO | Chief Tech/Sci/R&D Officer | - | - |
Handan He
CTO | Chief Tech/Sci/R&D Officer | - | 19-10-06 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jinzi Wu
CEO | Chief Executive Officer | 61 | - |
Jiong Gu
BRD | Director/Board Member | 51 | 18-03-31 |
Chief Operating Officer | 50 | 19-03-12 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.78% | 4 M€ | -27.92% | ||
0.00% | 34 M€ | +4.26% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 1.35 | -2.88% | 1 646 000 |
24-05-16 | 1.39 | 0.00% | 1,778,000 |
24-05-14 | 1.39 | -2.80% | 728,000 |
24-05-13 | 1.43 | +0.70% | 439,000 |
24-05-10 | 1.42 | +1.43% | 1,048,000 |
Delayed Quote Hong Kong S.E., May 17, 2024 at 04:08 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.53% | 180M | |
-2.32% | 92.59B | |
+3.16% | 41.43B | |
-11.10% | 33.49B | |
+53.87% | 25.06B | |
-9.41% | 12.77B | |
-12.25% | 11.58B | |
-44.00% | 11.35B | |
+5.32% | 8.97B | |
-6.32% | 8.3B |
- Stock Market
- Equities
- 1672 Stock